Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
CINCINNATI—Spencer S. Lee, the executive vice president of Chemed Corp (NYSE:CHE), recently sold a significant portion of his holdings in the company. The $8.8 billion healthcare services company has seen its stock surge nearly 10% in the past week, with InvestingPro data indicating the stock is currently in overbought territory. According to a regulatory filing with the Securities and Exchange Commission, Lee sold 1,326 shares of Chemed’s capital stock on March 3, 2025. The shares were sold at a weighted average price of $592.25, amounting to a total transaction value of $785,323. Based on InvestingPro’s Fair Value analysis, the stock appears to be fairly valued at current levels.
The filing notes that the shares were sold in multiple transactions at prices ranging from $587.36 to $599.61. Following this sale, Lee retains ownership of 17,627 shares in the company. Despite this insider sale, InvestingPro analysis reveals management has been actively buying back shares, and the stock typically trades with low price volatility. Subscribers can access 12 additional ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Chemed Corporation reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $6.83, compared to the forecasted $6.78. The company’s revenue also exceeded projections, reaching $640 million against the anticipated $636.1 million. The VITAS Healthcare segment was a significant contributor, with a 17.4% increase in revenue year-over-year, despite a slight decline in the Roto Rooter segment’s revenue. Chemed has set its full-year 2025 EPS guidance between $24.95 and $25.45, up from $23.13 in 2024.
Additionally, Chemed’s recent acquisition of Covenant Health is meeting internal financial projections, contributing positively to the company’s performance. Analysts from RBC Capital Markets noted the company’s strong operating performance, particularly in the VITAS segment, which continues to show robust growth. The company anticipates continued expansion, especially in Florida, where it has been awarded a Certificate of Need in Marion County. Chemed’s management has also emphasized strategic initiatives to manage Medicare cap challenges, ensuring sustainable growth for VITAS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.